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The anti-inflammatory actions of the nonapeptide antiflammin-2, identified by homology 
with uteroglobin and annexin-A1 sequences, have been described in some detail, yet its 
mechanisms of action remain elusive. Since recent data indicate an involvement of the 
formyl peptide receptor (FPR)-like 1 (or FPRL-1) in the effects of annexin-A1, we have 
tested here the effect of antiflammin-2 with respect to this receptor family. Using HEK-
293 cells expressing either human FPR and FPRL-1, and an annexin-A1 peptide as tracer 
([125I-Tyr]-Ac2-26), we found that antiflammin-2 competed for binding only at FPRL-1, and 
not FPR, with an approximate EC50 of 1 μM. In line with data produced for the full-length 
protein, genuine receptor activation by antiflammin-2 was confirmed by rapid 
phosphorylation of extracellular-regulated kinase 1 and 2. Finally, study of the neutrophil 
interaction with activated endothelium under flow demonstrated an inhibitory effect of 
antiflammin-2, thus providing functional support to a role for the antiflammin-2/FPRL-1 
anti-inflammatory axis.  
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annexin-A1, ALX, anti-inflammatory agents, peptides, FPR, signal transduction, flow chamber 
 
INTRODUCTION 
Annexin-A1 (ANXA1), originally termed lipocortin 1, is a glucocorticoid-regulated protein with intrinsic 
anti-inflammatory properties. This mediator acts on several arms of the host response, however its major 
effects are exerted on neutrophil trafficking, activation, and life span[1,2]. It is worth noting that the 
antimigratory effects of ANXA1 have been reproduced by peptides derived from the N-terminal region, 
both in vivo[3,4] as well as in neutrophil/endothelium interactions in static systems in vitro[5,6]. In 
particular, a peptide termed Ac2-26 (acetyl-AMVSEFLKQAWIENEEQEYVVQTVK, Mr, 3050) was 
originally found to retain the antimigratory and antioedema effects of the full-length protein in several 
models of acute inflammation[7,8]. A new interest in the ANXA1 field has been generated by the recent 
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observation that the protein and peptide Ac2-26 bind to a specific class of G-protein coupled 7 
transmembrane receptors, the formyl-peptide receptors (FPR)[9,10].  
Antiflammin-2 (AF-2) is a nonapeptide identified by sequence homology between two proteins with 
putative antiphospholipase A2 activity, uteroglobin and ANXA1[11]. Whereas the relevance of the direct 
inhibition of phospholipase A2 has been discussed[12], there are no doubts that AF-2, as well as its 
counterpart on uteroglobin termed AF-1, exerts anti-inflammatory activities when injected into recipient 
animals[13,14,15]. Supported by the novel notion that ANXA1 and its N-terminal–derived peptides 
activate members of the formyl peptide receptor (FPR) family, we questioned here whether AF-2 could 
also interact with these receptors. Indeed, structural analysis revealed that, in the presence of calcium 
ions, the AF-2 sequence would be exposed on the ANXA1 protein surface[16], therefore potentially being 
able to mediate or sustain protein-protein interactions. Out of three members so far described within this 
family, and termed FPR, FPRL-1, and FPRL-2, our analysis was restricted to the former two, since 
expressed by the human neutrophils[17], a cell type susceptible to AF-2 inhibitory effects[6,18]. 
MATERIALS AND METHODS 
Peptides 
AF-2 (HDMNKVDK, corresponding to residues 245-254 of human ANXA1, Mr 1084), the ANXA1 N-
terminal peptide, Ac2-26 (AMVSEFLKQAWFIENEEQEYVQTV corresponding to residues 2-26 of 
human ANXA1, Mr 3096), and the D-conformer of an FPRL-1-specific agonist W-peptide (WKYMVm, 
Mr 856)[19] were prepared by the Advanced Biotechnology Centre (Imperial College School of 
Medicine, London) using solid-phase stepwise synthesis. In all cases, purity was more than 90% as 
assessed by HPLC and capillary electrophoresis (data supplied by manufacturer). The nonspecific FPR 
family antagonist Boc2 (N-t-butyloxycarbonyl-Phe-DLeu-Phe-DLeu-Phe) was obtained from ICN 
Pharmaceuticals (Basingstoke, Hampshire), whereas peptide WRWWWW was from Calbiochem 
(Darmstadt, Germany). The N-terminal–derived peptide of annexin-1, Ac2-26 was iodinated on tyrosine 
21 with a specific activity of 2000 Ci/mmol ([125I-Tyr]-Ac2-26, Amersham Biosciences, Custom Service) 
for subsequent binding studies. 
Receptor Cloning 
Cloning and stable expression of the human FPR and FPRL-1 receptors was performed employing 
standard techniques. The cDNAs encoding the open reading frame of both receptors were obtained by 
PCR amplification of U-937 cDNA library. PCR was performed using specific oligonucleotide primers 
introducing a HindIII restriction site immediately 5’ to the initial ATG site and a NotI site 3’ to the stop 
codon of the receptor DNA. The oligonucleotide sequences used were as follows: FPR, forward primer, 
5’-GCG CAA GCT TAT GGA GAC AAA TTC CTC TCT CCC C, reverse primer, 5’-GCG CGG CCG 
CTC ACT TTG CCT GTA ACT CCA CCT CTG C and ALXR, forward primer, 5’-GCG CAA GCT 
TAT GGA AAC CAA CTT CTC CAC TCC TC, reverse primer, 5’-GCG CGG CCG CTC ACA TTG 
CCT GTA ACT CAG TCT CTG C). PCR products were digested, gel purified, and ligated in to 
pRc/CMV expression vector (Invitrogen, Paisley, Scotland) by sticky end ligation. Verification of the 
correct receptor construct was confirmed by sequencing. FPR and ALXR constructs were used to stably 
transfect HEK-293 cells using Fugene 6™ transfection reagent (Roche, Lewes, East Sussex) according to 
manufacturer’s instructions. Briefly, 2 μg of plasmid DNA was used to transfect HEK-293 cells (2 × 105 
cells/well in 6-well plates) cultured in supplemented Eagle’s minimum essential medium (EMEM). The 
medium was changed approximately 12 h later and cells left for a further 36 h prior to addition of 800 
μg/ml neomycin (Invitrogen, Paisley, Scotland) to select for transfectants, which were subsequently 
maintained in 400 μg/ml neomycin.  
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Receptor Binding Assay 
Aliquots (106 cells/ml) of either FPR-HEK– or FPRL-1-HEK–transfected cells were incubated with 
increasing concentrations of cold Ac2-26 (0.03–50 μM) and a fixed concentration (50 nM) of [125I-Tyr]-
Ac2-26 for 1 h in PBS supplemented with 1 mM CaCl2 at 4°C as described[20,21]. The bound and 
unbound tracers were separated by filtration through Whatman GF/C glass microfibre filters using a 
vacuum manifold, prior to γ-counting. Identical competition experiments were performed for the other 
ligands, AF-2 and W-peptide. 
Assessment of ERK Activation 
Activation of ERK was assessed by western blotting using specific antibodies to both phosphorylated and 
total ERK (Cell Signalling Technology, Hitchin, Hertfordshire). FPRL-1–transfected HEK-293 cells were 
seeded at 1–2 × 106 cells/well in 6-well plates in supplemented EMEM for approximately 18 h. Prior to 
addition of agonists, the medium was changed and serum-free EMEM was added followed by addition of 
the relevant agonists for the reported times[21]. Cell activation was terminated by placing the cells on ice, 
aspirating the medium, and immediately lysing the cells in boiling lysis buffer (50 mM Tris-HCl pH 6.8, 
1% NP-40, 2% SDS, 10% glycerol). Total protein was determined by the BCA method (Perbio 
Bioscience, Cramlington, Northumberland) followed by addition of 100 mM DTT and 0.1% bromophenol 
blue and heat denaturation prior to SDS-PAGE on 10% gels. Separated proteins were electrotransferred to 
nitrocellulose membranes (Hybond-C, Amersham Biosciences) presoaked in transfer buffer (25 mM Tris, 
192 mM glycine, 20% methanol) at 100 mA per blot for 60 min. Membranes were blocked with 5% 
nonfat milk in Tris-buffered saline, pH 7.4 (50 mM Tris-HCl, 150 mM NaCl, and 0.1% Tween-20) for 60 
min, followed by overnight incubation at 4°C in the relevant primary antibody (1:1000), and finally 
detection for 1 h with an antirabbit secondary antibody HRP-conjugate (1:2000, DakoCytomation, Ely, 
Cambridgeshire). Immunoreactive protein bands were detected by enhanced chemiluminescence (ECL, 
Amersham Biosciences). Developed Hyperfilm (Amersham Biosciences) was scanned and densitometric 
analysis performed with NIH Image version 1.63. 
Flow Chamber Assay 
Confluent human umbilical vein endothelial cell (HUVEC; Promocell, Heidelberg, Germany) monolayers 
(up to passage 4) were stimulated with TNF-α (10 ng/ml; Sigma) for 4 h. Experiments with healthy 
volunteers were approved by the local Research Ethics Committee (P/00/029 ELCHA). Blood was 
collected into 3.2% sodium citrate and diluted 1:1 in RPMI 1640 (Sigma, Poole, Dorset) before separation 
through a double density gradient as described[22]. After neutrophil isolation and washing, contaminating 
erythrocytes were removed by hypotonic lysis. Neutrophils were diluted to 1 × 106/ml in Dulbecco 
phosphate buffer saline (DPBS) supplemented with Ca2+ and Mg2+, and incubated with or without 
ANXA1 or peptide AF-2 prior to flow for 10 min at 37°C. The flow chamber was placed under a Nikon 
Eclipse TE3000 microscope with 100× magnification (Nikon, Inc., Melville, NY) and neutrophils (1 × 
106/ml) were perfused over the endothelial monolayers at a constant rate of 1 dyn/cm2 using a syringe 
pump (Harvard Apparatus, South Natick, MA). After 8 min of perfusion, six evenly spaced fields moving 
in a horizontal axis were recorded for 10 sec each, using a Q-imaging Retiga EXi digital video camera 
(Q-imaging, Burnaby, Canada) onto a computer running Streampix capture software (Norpix Inc., 
Montreal, Canada). Video sequences were then loaded into ImagePro-Plus software (Media Cybernetics, 
Wokingham, Berkshire) for analysis. Neutrophils were manually tagged and their movements on the 
endothelium monitored. The total number of interacting cells was quantified, as initial cell capture, and 
further classified as either rolling or firmly adherent (cells that remained stationary for the 10-sec 
observation period) as described in the literature[23]. 
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Data Handling and Statistical Analysis 
Experiments were performed in duplicate or triplicate and repeated at least three times. In the case of flow 
experiments, the six frames from each experiment were taken as a mean for comparison to repeat 
experiments. Within each set of experiments, where applicable, different blood donors were used for each 
repetition. Data are reported as mean ± SEM and statistical differences were determined by analysis of 
variance followed by the Dunnett’s test. 
RESULTS 
Competition Binding in Transfected Cells 
The ANXA1-derived nonapeptide, AF-2, and the synthetic D-conformer hexapeptide, W-peptide 
(WKYMVm), selectively displaced [125-I]-Ac2-26 from FPRL-1-HEK cells (Fig. 1). Out of three distinct 
experiments, approximate mean EC50 values of 1.21 μM (AF-2) and 0.29 μM (W-peptide), with Hill 
coefficients close to 1, could be calculated. 
 
FIGURE 1. Competition binding with AF-2 and W-peptide ligands on 
FPRL-1 HEK cells. Competition binding curves for AF-2 (●) and W-
peptide (○) in FPRL-1 HEK cells. Both peptides displaced [125I-Tyr]-
Ac2-26 tracer from binding to FPRL-1 HEK cells and approximate EC50 
and Hill constant are reported. Data presented as mean ± SEM of three 
independent experiments. 
In contrast, neither AF-2 nor W-peptide (Figs. 2a and 2b, respectively) significantly displaced the 
tracer off FPR-HEK cells. 
Postreceptor Signalling 
Following the demonstration of a direct physical interaction between AF-2 and W-peptide with FPRL-1, 
we then tested if activation of one of the major MAP kinase pathways was observed, choosing ERK 
kinase as this has been shown to be associated with post-FPRL-1 signalling events[21,24]. 




FIGURE 2. Lack of competition binding with AF-2 and W-peptide ligands to 
FPR HEK cells. Lack of displacement of the [125I-Tyr]-Ac2-26 tracer by AF-2 
(a) and W peptide (b) on FPR-HEK cells. Data presented as mean ± SEM of 
four independent experiments. 
Incubation of AF-2 (10 μM) between 2 and 30 min with FPRL-1 HEK cells resulted in a rapid time-
dependent activation of ERK 1/2 (Fig. 3a). In a separate analysis, we tested all FPRL-1 agonists of the 
study in this assay, finding reproducible activation of this MAP kinase (Fig. 3b), by all agonists. 
Functional Studies 
Finally, we tested if, by analogy to ANXA1[21], AF-2 could affect neutrophil interaction with the 
endothelium, a process charcaterised, and dependent on, FPRL-1 activation. 
Incubation with AF-2 (10 μM) produced a marked inhibition of neutrophil capture (>60%) and rolling 
(>80%), compared to controls, without significantly modifying the extent of neutrophil adhesion (Figs. 
4a–c). The effects of AF-2 effects were concentration dependent, with a reduced degree of inhibition 
when lower concentrations of the anti-inflammatory peptide (1–3 μM) were applied (data not shown). In 
addition, neutrophil incubation with the FPRL-1 selective synthetic antagonist WRWWWW (10 μM) 
significantly prevented the effect of the maximally active concentration (10 μM) of AF-2 on cell capture 
and rolling. This inhibitory effect was reproduced by neutrophil incubation with the pan-FPR-family 
receptor antagonist Boc2 (10 μM). 




FIGURE 3. AF-2–induced ERK activation in FPRL-1 HEK cells. Panel a, 
time-dependent increases in ERK activation in FPRL-1-HEK cells incubated 
with 10 µM AF-2. Panel b, ERK phosphorylation produced by FPRL-1-HEK 
cell incubation (10 min) with peptide Ac2-26 (10 µM), ANXA1 (0.5 µM), 
AF-2 (10 µM), or W-peptide (10 µM). Data are representative of two to four 
independent experiments.  
DISCUSSION 
This study demonstrates for the first time a direct and selective interaction between the ANXA1 core-
derived peptide AF-2 and the human FPRL-1 receptor. The FPRL-1-specific synthetic ligand W-peptide 
confirmed the selectivity of the assays employed for FPRL-1. These biochemical data are linked to 
functional signalling and cell-to-cell interaction analyses. We propose that this specific G-protein coupled 
receptor mediates at least some of the anti-inflammatory properties of AF-2. 
The majority of studies investigating the role(s) of the FPR family in mediating the biological actions 
of ANXA1 have focussed on neutrophils[10,20,25]. However, human neutrophils are known to express 
both FPR and FPRL-1 receptors[17], making it difficult to dissect out the relative contribution of different 
receptor subtypes. A truncated N-terminal peptide of ANXA1 (residues 9-25), inhibited transendothelial 
neutrophil migration, calcium transients, and superoxide release in human neutrophils, effects mediated 
by the FPR receptor[25]. The N-terminal Ac2-26 peptide also causes calcium transients and chemotaxis 
of HEK-293 cells transfected with all three members of the human FPR family[10]. Our recent functional 
study supports this hypothesis, since in controlled in vitro experimental conditions, Ac2-26 bound to both 
FPR and FPRL-1 transfected HEK cells[21], suggesting that this molecule lacks any preassumed 
selectivity for a given FPR subtype. 
In contrast to peptide Ac2-26, a good degree of selectivity was retained by another ANXA1-derived 
anti-inflammatory sequence: We showed here that AF-2 possessed selectivity for FPRL-1 in competition 
displacement experiments, with an EC50 value in the low micromolar range (1.2 μM). Such data reinforce 
the notion that the specific actions of ANXA1 might not be entirely mediated by its N-terminal region and 
that other sites on the molecule could be important. Interestingly, binding of AF-2 to FPRL-1 might occur 
with a degree of positive cooperativity as indicated by a Hill coefficient greater than 1 (1.18), which may 
have implications for the physicochemical and possible structure-activity relationship that this peptide 
may have with the receptor. 




FIGURE 4. Effect of AF-2 on neutrophil interaction with HUVEC under 
flow. Neutrophils were incubated with 10 µM AF-2 alone, with 10 µM 
WRWWWW or with 10 µM Boc2, for 10 min prior to flow over TNF-α 
stimulated (10 ng/ml, 4 h) HUVEC. Neutrophil-endothelium interactions were 
quantified off-line. (a) Number of neutrophils captured. (b) Number of rolling 
neutrophils. (c) Number of firmly adherent neutrophils. Data are presented as 
mean ± SEM of four to six independent experiments. ∗ p < 0.05 vs. control 
group; # p < 0.05 vs. AF-2 alone group. 
In the absence of calcium, the ANXA1 N-terminal is associated with the third core domain region that 
is responsible for calcium binding (residues 242-257), that contains the AF-2 sequence[26]; this 
represents the inactive conformation of the protein[27]. However, on binding to membrane phospholipids, 
such as phosphatidylserine, ANXA1 affinity for calcium increases[28]. In this situation, ANXA1 changes 
conformation[27], possibly exposing the AF-2 sequence (third repeat; residues 247-255), which could 
then be potentially involved in determining biological activity or receptor binding. Interestingly, direct 
ANXA1 interaction with FPRL-1 occurs in the extracellular milieu, where calcium concentration is > 1 
mM[20]. 
The observation that W-peptide also bound specifically to the FPRL-1 confirms a relative degree of 
nonspecificity for peptide ligand binding at this receptor, whose natural ligands include the anti-
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inflammatory lipid mediator LXA4[29], serum amyloid A[30], humanin[31], and ANXA1[20]. The 
synthetic W-peptide was employed in the present study to confirm the FPRL-1 specificity observed for 
AF-2[32]. W-peptide binds to both the FPRL-1 and FPRL-2 where it causes receptor phosphorylation 
with a calculated Kd value of 0.16 μM[33] within the range of what found in this study (0.29 μM).  
In addition to receptor binding, we show for the first time AF-2 activated FPRL-1. Similarly to what 
we recently reported for ANXA1[21], AF-2 addition to cells provoked transient activation of ERK-1 and 
ERK-2. This effect was rapid and specific since mock-transfected cells failed to demonstrate any 
increases in ERK activation (data not shown). Sustained ERK activation in response to constitutive 
overexpression of ANXA1 has been observed in RAW 264.7 macrophages and is associated with reduced 
cell proliferation[34,35]. Activation of this specific MAP kinase pathway has been reported for FPRL-1 
and other members of this family[36,37]. 
The study was completed by determining the effect of AF-2 on neutrophil interaction with activated 
endothelial cells as monitored under flow. In line with the parent molecule[21], AF-2 inhibited this cell-
to-cell response, the effect being genuinely attributable to FPRL-1, since it could be reversed by the 
selective antagonist WRWWWW[38]. These results are of great importance since they provide an 
unequivocal link between the biochemical data discussed above and the anti-inflammatory nature of this 
nonapeptide. 
In summary, the present data illustrate for the first time selective binding of AF-2 to human FPRL-1, 
providing a potential mechanism of action responsible for the anti-inflammatory properties of this 
nonapeptide. Such data may also provide insights in to the potential active conformations of ANXA1, 
required to attain optimal receptor activation. The hypothesis put forward some time ago[39] in which 
two distinct regions of the protein (the N-terminal region and the antiflammin sequence) might be 
responsible for receptor binding and cooperate was reinforced by data from our functional assays. 
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